Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.69 |
| ▸ | FBP1 | P09467 | 9/20 | 0.67 |
| ▸ | TLR4 | O00206 | 2/20 | 0.58 |
| ▸ | TLR2 | O60603 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | RELA | Q04206 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16632342 | 1.00 | PTGS2 (0.69) | PTGS2FBP1TLR4TLR2MAPT | |
| SCHEMBL30307363 | 0.89 | FBP1 (0.58) | PTGS2FBP1TLR4TLR2MAPT | |
| SCHEMBL509742 | 0.88 | TLR4 (0.71) | PTGS2FBP1TLR4TLR2MAPT | |
| SCHEMBL509743 | 0.88 | TLR4 (0.71) | PTGS2FBP1TLR4TLR2MAPT | |
| SCHEMBL17070027 | 0.84 | FBP1 (0.64) | PTGS2FBP1TLR4TLR2MAPT | |
| SCHEMBL5688280 | 0.84 | TLR4 (0.66) | PTGS2FBP1TLR4TLR2MAPT | |
| SCHEMBL5688276 | 0.84 | TLR4 (0.66) | PTGS2FBP1TLR4TLR2MAPT | |
| SCHEMBL13515394 | 0.84 | TLR4 (0.66) | PTGS2FBP1TLR4TLR2MAPT | |
| SCHEMBL17070015 | 0.83 | FBP1 (0.62) | FBP1TLR4TLR2MAPTALDH1A1 | |
| SCHEMBL3829457 | 0.83 | FBP1 (0.62) | PTGS2FBP1TLR4TLR2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240366586-A1 | METHODS AND AGENTS FOR MODULATING THE IMMUNE RESPONSE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-11-07 | — | — | US | claimed |
| WO-2023034413-A2 | METHODS AND AGENTS FOR MODULATING THE IMMUNE RESPONSE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-09 | — | — | WO | claimed |
| US-20240366586-A1 | METHODS AND AGENTS FOR MODULATING THE IMMUNE RESPONSE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-11-07 | — | — | US | disclosed |
| WO-2023034413-A2 | METHODS AND AGENTS FOR MODULATING THE IMMUNE RESPONSE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-09 | — | — | WO | disclosed |
| US-9206124-B2 | Treatment of drug-resistant cancer with 2-aryl-2-(3-indolyl) acetohydroxamates | NEW MEXICO TECHNICAL RESEARCH FOUNDATION (US) | 2015-12-08 | — | — | US | disclosed |
| US-20150105439-A1 | TREATMENT OF DRUG-RESISTANT CANCER WITH 2-ARYL-2-(3-INDOLYL) ACETOHYDROXAMATES | NEW MEXICO TECH UNIVERSITY RESEARCH PARK CORPORATION | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105439-A1 | TREATMENT OF DRUG-RESISTANT CANCER WITH 2-ARYL-2-(3-INDOLYL) ACETOHYDROXAMATES | AADAC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ABCC1 | PTGS2 2610/4885FBP1 4633/4885TLR4 3388/4885 |
| US-20240366586-A1 | METHODS AND AGENTS FOR MODULATING THE IMMUNE RESPONSE | IL15, IL2, IL17A | PTGS2 186/4885FBP1 2778/4885TLR4 887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.